You are viewing the site in preview mode
Skip to main content
|
Factors
|
Grade ≥ 2 RP (N = 45)
|
Grade ≥ 3 RP (N = 18)
|
|---|
|
Grade < 2 RP
|
Grade ≥ 2 RP
|
p value
|
Grade < 3 RP
|
Grade ≥ 3 RP
|
p value
|
|---|
|
Gender
| | |
0.175
| | |
0.439
|
|
Male
|
37
|
44
| |
63
|
18
| |
|
Female
|
5
|
1
| |
6
|
0
| |
|
Age (years)
| | |
0.256
| | |
0.659
|
|
< 70
|
25
|
32
| |
46
|
11
| |
|
≥ 70
|
17
|
13
| |
23
|
7
| |
|
Smoking history
| | |
0.165
| | |
0.493
|
|
No
|
15
|
10
| |
21
|
4
| |
|
Yes
|
27
|
35
| |
48
|
14
| |
|
Pathological type
| | |
0.503
| | |
0.219
|
|
NSCLC
|
29
|
28
| |
43
|
14
| |
|
SCLC
|
13
|
17
| |
26
|
4
| |
|
Tumor stage
| | |
0.092
| | |
0.692
|
|
I
|
2
|
0
| |
2
|
0
| |
|
III
|
28
|
36
| |
51
|
13
| |
|
IV
|
4
|
6
| |
7
|
3
| |
|
Postoperative
|
8
|
3
| |
9
|
2
| |
|
Tumor location
| | |
0.043
| | |
0.120
|
|
Upper lobe
|
32
|
25
| |
48
|
9
| |
|
Middle or lower lobe
|
10
|
20
| |
21
|
9
| |
|
Chemotherapy with gemcitabine in the past
| | |
0.856
| | |
0.031
|
|
No
|
26
|
27
| |
46
|
7
| |
|
Yes
|
16
|
18
| |
23
|
11
| |
|
Concurrent chemotherapy
| | |
0.142
| | |
0.782
|
|
No
|
30
|
38
| |
53
|
15
| |
|
Yes
|
12
|
7
| |
16
|
3
| |
|
Distribution of subclinical ILD
| | |
0.275
| | |
0.157
|
|
Lateral
|
7
|
4
| |
11
|
0
| |
|
Bilateral
|
35
|
41
| |
58
|
18
| |
|
Morphology of subclinical ILD
| | |
0.399
| | |
0.137
|
|
No honeycombing
|
34
|
33
| |
56
|
11
| |
|
Honeycombing
|
8
|
12
| |
13
|
7
| |
|
Percentage of lung volume affected in subclinical ILD
| | |
0.171
| | |
0.037
|
|
< 25%
|
38
|
36
| |
62
|
12
| |
|
≥ 25%
|
4
|
9
| |
7
|
6
| |
|
Pulmonary emphysema
| | |
0.658
| | |
0.775
|
|
No
|
6
|
8
| |
12
|
2
| |
|
Yes
|
36
|
37
| |
57
|
16
| |
|
Total dose (Gy)
| | |
0.834
| | |
0.349
|
|
EQD2 < 60.0
|
13
|
13
| |
19
|
7
| |
|
EQD2 ≥ 60.0
|
29
|
32
| |
50
|
11
| |
|
Single fraction dose
| | |
0.826
| | |
1.000
|
|
2.0 Gy
|
38
|
39
| |
61
|
16
| |
|
> 2.0 Gy, ≤ 3.0 Gy
|
4
|
6
| |
8
|
2
| |
|
FVC%
|
89.53 ± 14.50
|
92.15 ± 25.83
|
0.632
|
89.93 ± 22.58
|
94.53 ± 17.75
|
0.472
|
|
FEV1/ FVC (%)
|
74.71 ± 9.05
|
74.05 ± 9.89
|
0.782
|
74.57 ± 8.52
|
73.56 ± 12.40
|
0.720
|
|
MLD (Gy)
|
11.52 ± 3.36
|
12.97 ± 2.45
|
0.024
|
12.00 ± 3.15
|
13.29 ± 2.11
|
0.106
|
|
V5 (%)
|
46.07 ± 12.51
|
48.24 ± 9.54
|
0.363
|
46.19 ± 11.69
|
51.06 ± 7.25
|
0.097
|
|
V10 (%)
|
33.14 ± 9.84
|
35.00 ± 7.20
|
0.316
|
33.68 ± 9.26
|
35.72 ± 5.04
|
0.216
|
|
V20 (%)
|
20.62 ± 6.88
|
21.89 ± 4.46
|
0.314
|
21.10 ± 6.14
|
21.94 ± 4.05
|
0.583
|
|
V30 (%)
|
14.24 ± 5.64
|
16.07 ± 4.08
|
0.085
|
14.91 ± 5.12
|
16.22 ± 4.22
|
0.321
|
|
GTV (cc)
|
97.80(3.75–398.99)
|
120.17(20.47–497.86)
|
0.288
|
105.40(3.75–398.99)
|
105.14(20.47–497.86)
|
0.991
|
|
PTV (cc)
|
355.88(69.26–2601.29)
|
392.60(300.77–1070.38)
|
0.139
|
379.12(69.26–2601.29)
|
349.95(257.32–1070.38)
|
0.608
|
- RP, radiation pneumonitis; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer; ILD, interstitial lung disease; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; FVC%, percentage forced vital capacity; EQD2, equivalent dose in 2.0 Gy/(fraction per day); MLD, mean lung dose; V5, percentage of lung volume receiving ≥ 5 Gy; V10, percentage of lung volume receiving ≥ 10 Gy; V20, percentage of lung volume receiving ≥ 20 Gy; V30, percentage of lung volume receiving ≥ 30 Gy; GTV, gross tumor volume; PTV, planning target volume
